데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
110655-58-8CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H]3CCCN3C(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H]3CNCCCC[C@@H](C(=O)O)NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H]([C@@H](O)C(=O)O)NC(=O)[C@H](CSC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CS[C@H]4C)C(=O)N[C@@H](CS[C@H]2C)C(=O)N3)NC1=O110655-58-8CHEBI:141991안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
용도Cinnamycin (lanthiopeptin) is a high molecular weight tricyclic antibiotic produced by several species of Streptoverticillium. Cinnamycin is a potent indirect inhibitor of phospholipase A2, acting by specifically sequestering phosphatidylethanolamine (PE), a major component of the mammalian plasma cell membrane. Cinnamycin induces trans-bilayer phospholipid movement in cell membranes to expose internally bound PE. At high surface concentrations of PE, cinnamycin induces membrane re-organisation including membrane fusion and alteration of gross morphology.
일반 설명Cinnamycin is synthesized after proteolytic cleavage from core peptide and takes up a compact globular structure.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…